

Chien-Wei Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9043344/publications.pdf>

Version: 2024-02-01

212
papers

6,142
citations

108046

37
h-index

107981

68
g-index

214
all docs

214
docs citations

214
times ranked

7324
citing authors

#	ARTICLE	IF	CITATIONS
1	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 61-69.	0.6	4
2	Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 30-41.	0.6	7
3	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 19-27.	0.7	2
4	Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 152-159.	0.6	3
5	A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 649.	1.7	17
6	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. <i>International Journal of Clinical Oncology</i> , 2022, 27, 739-748.	1.0	5
7	Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. <i>Cells</i> , 2022, 11, 634.	1.8	8
8	Differential prognoses among male and female patients with hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 554-565.	0.6	11
9	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 679-686.	0.6	5
10	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. <i>Scientific Reports</i> , 2022, 12, 8343.	1.6	5
11	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210994.	1.4	1
12	Liver tumor encapsulating the gallbladder. , 2022, , .		0
13	Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 385-395.	1.5	14
14	Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1730-1738.	1.1	10
15	Rpeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 956-964.	0.8	15
16	The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 136-143.	0.6	8
17	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 287-289.	1.9	2
18	Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 465-471.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. <i>Cancers</i> , 2021, 13, 1729.	1.7	14
20	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 472-477.	0.6	2
21	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 722-734.	0.6	1
22	Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. <i>Hepatology</i> , 2021, 74, 641-655.	3.6	27
23	Easy albuminâ€“bilirubin score as a new prognostic predictor in hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 1129-1138.	1.8	17
24	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3196-3203.	1.4	21
25	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , 2021, 13, 4325.	1.7	8
26	Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1563-1571.	0.8	14
27	IDDF2021-ABS-0071â€“...Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. , 2021, , .		1
28	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. <i>Hepatology International</i> , 2021, 15, 1421-1430.	1.9	15
29	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. <i>American Journal of Cancer Research</i> , 2021, 11, 3711-3725.	1.4	4
30	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. <i>American Journal of Cancer Research</i> , 2021, 11, 5526-5542.	1.4	0
31	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 218-229.	0.8	19
32	The correlation between fatty liver disease and chronic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 42-50.	0.8	16
33	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 610-620.	0.8	13
34	Albuminâ€“bilirubin gradeâ€“based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 205-214.	1.9	28
35	A New Prognostic Model Based on Albuminâ€“Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. <i>Digestive Diseases and Sciences</i> , 2020, 65, 658-667.	1.1	14
36	Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 18-24.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 365-372.	0.8	2
38	Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 997-1008.	1.9	18
39	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. <i>Scientific Reports</i> , 2020, 10, 17259.	1.6	7
40	Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1676-1685.	0.8	3
41	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. <i>Cancers</i> , 2020, 12, 1130.	1.7	10
42	Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion. <i>Journal of Biomedical Science</i> , 2020, 27, 65.	2.6	7
43	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	1.9	20
44	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3925.	1.6	18
45	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. <i>Scientific Reports</i> , 2020, 10, 2006.	1.6	7
46	Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2020, 30, 1249-1257.	1.1	16
47	Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 125-133.	0.6	4
48	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 238-238.	0.7	17
49	A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1704-1712.	1.9	58
50	A Novel AURKA Mutant-Induced Early-Onset Severe Hepatocarcinogenesis Greater than Wild-Type via Activating Different Pathways in Zebrafish. <i>Cancers</i> , 2019, 11, 927.	1.7	15
51	High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. <i>Cancers</i> , 2019, 11, 1549.	1.7	12
52	SAT-462-Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e836-e837.	1.8	0
53	Schistosomiasis infection-related cholangiocarcinoma. <i>Advances in Digestive Medicine</i> , 2019, 6, 132-133.	0.1	1
54	FRI-185-Virological and immunological predictors of long-term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e471.	1.8	1

#	ARTICLE	IF	CITATIONS
55	SAT-463-Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e837-e838.	1.8	0
56	Determination of the predictive factors for significant liver fibrosis assessed through transient elastography. <i>Advances in Digestive Medicine</i> , 2019, 6, 5-14.	0.1	2
57	Keep scalpel sheathed: A metastatic invasive ductal carcinoma mimics primary linitis plastica. <i>Advances in Digestive Medicine</i> , 2019, 6, 36-39.	0.1	0
58	Reply. <i>Hepatology</i> , 2019, 70, 440-441.	3.6	0
59	Towards a more comprehensive evaluation of liver fibrosis in patients with chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 807-808.	0.6	0
60	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 186-190.	0.6	3
61	An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 698-704.	0.6	15
62	Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 693-698.	0.6	7
63	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 2-10.	0.6	16
64	Less barium enema, more colonoscopy. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 312-317.	0.6	5
65	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. <i>Hepatology</i> , 2019, 69, 1151-1164.	3.6	22
66	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
67	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 776-781.	0.5	38
68	Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1230-1231.	1.9	1
69	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. <i>Scientific Reports</i> , 2018, 8, 843.	1.6	25
70	Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 230-239.e2.	0.5	30
71	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. <i>Scientific Reports</i> , 2018, 8, 4773.	1.6	26
72	Impact of etiological treatment on prognosis. <i>Hepatology International</i> , 2018, 12, 56-67.	1.9	12

#	ARTICLE	IF	CITATIONS
73	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	1.9	37
74	Same-day Versus Split-dose Bowel Preparation Before Colonoscopy. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 392-400.	1.1	34
75	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92
76	Outcomes of resection surgery for hepatocellular carcinoma: Does size matter?. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 89-91.	0.6	3
77	Hepatitis B virus and glomerulonephritis: Two silent killers. <i>Advances in Digestive Medicine</i> , 2018, 5, 111-112.	0.1	1
78	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1368-1377.	0.8	7
79	Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelialâ€Mesenchymal Transition Regulators and Stemness Genes. <i>Hepatology Communications</i> , 2018, 2, 1392-1407.	2.0	25
80	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 15074.	1.6	8
81	The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S713.	1.8	0
82	Propranolol treatment associated with better survival and reduced sepsis in cirrhotic patients with hepatic encephalopathy. <i>Journal of Hepatology</i> , 2018, 68, S711-S712.	1.8	0
83	Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 1075-1084.	1.9	16
84	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. <i>Liver Cancer</i> , 2018, 7, 335-358.	4.2	27
85	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAgâ€positive cancer patients undergoing chemotherapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1599-1607.	1.0	9
86	Proton pump inhibitors and risk of hepatocellular carcinoma: a population-based study. <i>Journal of Hepatology</i> , 2018, 68, S429.	1.8	1
87	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42577.	1.6	25
88	Acute kidney injury predicts mortality in cirrhotic patients with gastric variceal bleeding. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1859-1866.	1.4	18
89	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. <i>Radiology</i> , 2017, 285, 670-680.	3.6	88
90	Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. <i>Journal of Ethnopharmacology</i> , 2017, 196, 1-8.	2.0	7

#	ARTICLE	IF	CITATIONS
91	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 125-132.	0.6	24
92	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. <i>European Radiology</i> , 2017, 27, 2600-2609.	2.3	13
93	Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections. <i>PLoS ONE</i> , 2017, 12, e0178841.	1.1	2
94	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. <i>PLoS ONE</i> , 2017, 12, e0188552.	1.1	6
95	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-12.	0.7	14
96	Uterine cervical squamous cell carcinoma with duodenal metastasis causes obstructive jaundice. <i>Advances in Digestive Medicine</i> , 2017, 4, 76-79.	0.1	0
97	Low air temperature increases the risk of oesophageal variceal bleeding: a population and hospital-based case-crossover study in Taiwan. <i>Liver International</i> , 2016, 36, 856-864.	1.9	4
98	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 874-883.	0.7	51
99	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. <i>Scientific Reports</i> , 2016, 6, 29605.	1.6	37
100	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. <i>European Journal of Cancer</i> , 2016, 63, 25-33.	1.3	40
101	Staging for hepatocellular carcinoma: An embarrassment of riches. <i>Journal of Hepatology</i> , 2016, 64, 535-536.	1.8	8
102	Establishing a risk scoring system for predicting erosive esophagitis. <i>Advances in Digestive Medicine</i> , 2016, 3, 95-100.	0.1	2
103	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. <i>Journal of Hepatology</i> , 2016, 64, 601-608.	1.8	220
104	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. <i>PLoS ONE</i> , 2016, 11, e0155588.	1.1	37
105	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. <i>Medicine (United States)</i> , 2015, 94, e1808.	0.4	26
106	Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2015, 94, e1341.	0.4	21
107	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120443.	1.1	105
108	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-189.	0.6	18

#	ARTICLE	IF	CITATIONS
109	Prognosis of Early-Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1929.	0.4	32
110	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment. <i>Medicine (United States)</i> , 2015, 94, e1659.	0.4	8
111	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. <i>Medicine (United States)</i> , 2015, 94, e688.	0.4	30
112	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1772.	0.4	21
113	Healthy Chinese with benign pancreatic hyperenzymemia. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 623-626.	0.6	4
114	Vomiting and diarrhea in a woman with systemic lupus erythematosus. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 133-135.	0.6	3
115	Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. <i>Hepatology</i> , 2015, 61, 1870-1879.	3.6	63
116	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 2253-2261.	0.7	31
117	Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 404-409.	0.8	25
118	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 242-249.	1.1	33
119	Endoscopic ultrasonography assessment of para-esophageal varices predicts efficacy of propranolol in preventing recurrence of esophageal varices. <i>Journal of Gastroenterology</i> , 2015, 50, 342-349.	2.3	15
120	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0137852.	1.1	5
121	Valproic acid and hydralazine-modulated gemcitabine and cisplatin followed by doxorubicin in advanced hepatocellular carcinoma: A phase II study. <i>Journal of Clinical Oncology</i> , 2015, 33, e15119-e15119.	0.8	0
122	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-9.	0.6	12
123	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. <i>PLoS ONE</i> , 2014, 9, e99115.	1.1	8
124	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2014, 93, e264.	0.4	20
125	Application of serologic assays for diagnosing acute hepatitis E in national surveillance of a nonendemic area. <i>Journal of Medical Virology</i> , 2014, 86, 720-728.	2.5	28
126	Risk of oral antifungal agents-induced liver injury in Taiwanese. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 180-189.	1.1	51

#	ARTICLE	IF	CITATIONS
127	Vascular Invasion in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 734-741.	1.1	68
128	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. <i>Gastroenterology</i> , 2014, 147, 143-151.e5.	0.6	267
129	The Use of Ultrasound-guided Radiofrequency Ablation Therapy for Small Hepatocellular Carcinomas. <i>Journal of Medical Ultrasound</i> , 2014, 22, 7-8.	0.2	0
130	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child-Pugh Scores of 5 or 6. <i>Medicine (United States)</i> , 2014, 93, e348.	0.4	17
131	Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 702-711.	0.9	28
132	Î±-Fetoprotein-to-Total Tumor Volume Ratio Predicts Post-operative Tumor Recurrence in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 730-738.	0.9	23
133	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 645-654.	1.9	17
134	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. <i>Hepatology International</i> , 2013, 7, 188-198.	1.9	36
135	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2013, 20, 2035-2042.	0.7	17
136	Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. <i>Liver International</i> , 2013, 33, 616-623.	1.9	15
137	Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. <i>Hepatology</i> , 2013, 57, 112-119.	3.6	168
138	Wandering abdominal pain due to a floating gallbladder. <i>Digestive and Liver Disease</i> , 2013, 45, e13.	0.4	1
139	Risk of Hepato-Biliary Cancer After Cholecystectomy: a Nationwide Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 345-351.	0.9	19
140	Letter: pyogenic liver abscess and colorectal cancer — authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 165-166.	1.9	0
141	Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 348-356.	1.4	11
142	Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1849-1858.	1.4	10
143	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. <i>International Journal of Cancer</i> , 2013, 133, 2895-2902.	2.3	49
144	Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. <i>BMC Genomics</i> , 2013, 14, 736.	1.2	45

#	ARTICLE	IF	CITATIONS
145	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	1.1	76
146	CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS ONE, 2013, 8, e76798.	1.1	18
147	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-273.	0.6	18
148	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. PLoS ONE, 2013, 8, e58071.	1.1	26
149	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 2013, 8, e66457.	1.1	67
150	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-73.	0.6	7
151	The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection Surgery. Archives of Surgery, 2012, 147, 137.	2.3	60
152	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2012, 46, 789-795.	1.1	19
153	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. Journal of Clinical Gastroenterology, 2012, 46, 62-70.	1.1	56
154	Letter: pyogenic liver abscess is a red flag sign of hepatocellular carcinoma – authors’ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 906-907.	1.9	0
155	Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1581-1588.	1.4	11
156	Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clinical Radiology, 2012, 67, 429-436.	0.5	42
157	Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. Annals of Surgical Oncology, 2012, 19, 842-849.	0.7	108
158	Citrus reticulata peel improves patient tolerance of low-volume polyethylene glycol for colonoscopy preparation. Journal of the Chinese Medical Association, 2012, 75, 442-448.	0.6	8
159	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Digestive and Liver Disease, 2012, 44, 868-874.	0.4	10
160	Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: Extending the Indication for resection?. Surgery, 2012, 152, 809-820.	1.0	90
161	Outcome After Percutaneous Cholecystostomy for Acute Cholecystitis: a Single-Center Experience. Journal of Gastrointestinal Surgery, 2012, 16, 1860-1868.	0.9	66
162	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	1.9	20

#	ARTICLE	IF	CITATIONS
163	Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: A cohort study. <i>Journal of Hepatology</i> , 2012, 57, 1207-1213.	1.8	166
164	Hepatitis D Virus Isolates with Low Replication and Epithelial-Mesenchymal Transition-Inducing Activity Are Associated with Disease Remission. <i>Journal of Virology</i> , 2012, 86, 9044-9054.	1.5	11
165	Cancer risk in patients with pyogenic liver abscess: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 467-476.	1.9	43
166	Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34,346 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 560-568.	1.9	55
167	A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 551-559.	1.9	11
168	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 690-699.	1.4	12
169	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 79-86.	2.4	151
170	Hepatocellular Carcinoma With Sternal Metastasis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, e46-e47.	2.4	2
171	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1.	0.8	53
172	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 278-285.	1.1	28
173	Effect of Host and Viral Factors on Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α -2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	0.6	91
174	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical Nutrition</i> , 2011, 30, 647-652.	2.3	21
175	A Comparison of Prognosis between Patients with Hepatitis B and C Virus-related Hepatocellular Carcinoma Undergoing Resection Surgery. <i>World Journal of Surgery</i> , 2011, 35, 858-867.	0.8	87
176	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2011, 5, 975-984.	1.9	13
177	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. <i>Liver Transplantation</i> , 2011, 17, 556-566.	1.3	63
178	Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e171-e177.	1.1	29
179	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 691-699.	1.9	60
180	Selecting an optimal staging system for hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 3006-3014.	2.0	88

#	ARTICLE	IF	CITATIONS
181	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. <i>Liver International</i> , 2010, 30, 77-84.	1.9	34
182	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of Î±-fetoprotein. <i>Liver International</i> , 2010, 30, 1161-1168.	1.9	10
183	Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads. <i>Vaccine Journal</i> , 2010, 17, 1048-1053.	3.2	7
184	Pro-205 of large hepatitis delta antigen and Pro-62 of major hepatitis B surface antigen influence the assembly of different genotypes of hepatitis D virus. <i>Journal of General Virology</i> , 2010, 91, 1004-1012.	1.3	13
185	Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. <i>BMC Gastroenterology</i> , 2010, 10, 146.	0.8	33
186	Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. <i>Digestive and Liver Disease</i> , 2010, 42, 137-142.	0.4	35
187	The safety and probable therapeutic effect of routine use of antibiotics and simultaneously treating bleeding gastric varices by using endoscopic cyanoacrylate injection and concomitant esophageal varices with banding ligation: a pilot study. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 1141-1149.	0.5	11
188	Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. <i>Journal of Hepatology</i> , 2010, 52, 463-465.	1.8	11
189	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. <i>Journal of Hepatology</i> , 2010, 53, 108-117.	1.8	157
190	Hepatocellular Carcinoma With Presentation of Budd-Chiari Syndrome. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 93-96.	0.6	7
191	Systemic Amyloidosis Manifesting as a Rare Cause of Hepatic Failure. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 161-165.	0.6	8
192	Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. <i>Hepatology</i> , 2009, 50, 1464-1474.	3.6	321
193	Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?. <i>Liver International</i> , 2009, 29, 767-773.	1.9	19
194	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. <i>Journal of Hepatology</i> , 2009, 50, 779-788.	1.8	4
195	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 51, 890-897.	1.8	369
196	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 876-883.	1.1	25
197	Gastrointestinal bleeding because of hookworm infection diagnosed by capsule endoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1219.	0.8	3
198	Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. <i>Liver International</i> , 2008, 28, 1305-1313.	1.9	23

#	ARTICLE	IF	CITATIONS
199	Validation of the HCCâ€MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. <i>Clinical Transplantation</i> , 2008, 22, 469-475.	0.8	34
200	Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 40-44.	0.6	1
201	Hepatocellular Carcinoma With Invasion Into Right Atrium. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, e39-e40.	2.4	3
202	Hepatic Splenosis Diagnosed by Spleen Scintigraphy. <i>American Journal of Gastroenterology</i> , 2008, 103, 1842-1844.	0.2	6
203	Hepatitis B Surface Antigen Levels and Sequences of Natural Hepatitis B Virus Variants Influence the Assembly and Secretion of Hepatitis D Virus. <i>Journal of Virology</i> , 2008, 82, 2250-2264.	1.5	55
204	Autoimmune hepatitis combined with multiple viral infections. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 1122-1123.	0.8	1
205	Positive Selection of Hepatitis Delta Antigen in Chronic Hepatitis D Patients. <i>Journal of Virology</i> , 2007, 81, 4438-4444.	1.5	20
206	Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. <i>Gastroenterology</i> , 2006, 130, 1625-1635.	0.6	193
207	Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 336-342.	1.0	25
208	Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. <i>Journal of Viral Hepatitis</i> , 2003, 10, 277-284.	1.0	37
209	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 1187-1191.	1.4	13
210	Zafirlukast-induced acute hepatitis. <i>Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed</i> , 2002, 65, 553-6.	0.0	0
211	Right inguinal metastasis from hepatocellular carcinoma. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	1
212	Splenic artery pseudoaneurysm as a fatal complication of acute pancreatitis. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	0